Encoded Therapeutics, Inc. Announces $104 Million Series C Financing to Advance Lead Gene Therapy Program in Dravet Syndrome and Unveils its Precision Gene Therapy Platform
Summary
Encoded will use the funds to advance its lead program in Dravet Syndrome and its preclinical pipeline, as well as to leverage its platform to develop new therapeutics to treat severe genetic disorders. "We are pleased to join this distinguished group of investors in supporting Encodeds efforts to bring new gene therapies to diseases that cant be reached with existing therapeutics. The disorder is characterized by uncontrolled seizures, ataxia, significant developmental delays and an increased risk of early mortality due to sudden unexpected death in epilepsy (SUDEP). Encoded presented preclinical data from the Dravet Syndrome program at the 22nd Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) in Washington, D.C. in May. "Encoded represents an incredibly exciting addition to the gene therapy field and I look forward to working with this talented team to further develop and commercialize the pipeline of potentially transformative therapeutics for patients and families suffering from devasting diseases.